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The cardiac inward rectiﬁer K+ current (IK1), present in both
ventricular and atrial myocytes, has been suggested to play amajor role
in repolarization of the action potential and stabilization of the resting
membrane potential [1]. Cardiac IK1 channels are the heterotetrameric
assembly of different Kir2 subfamily members, including Kir2.1, Kir2.2
and Kir2.3 [1,2]. Kir2.1 (KCNJ2 or IRK1) is the major candidate gene
underlying cardiac IK1 [1,3] since most of the properties of Kir2.1
channels expressed in different types of cells are similar to those of
native cardiac IK1 [2]. Dysfunction of Kir2.1 channel [4–6], including
disruption of the channel's binding site for the membrane-associated
regulatory phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2)
[7–10] and impaired intracellular trafﬁcking of Kir2.1 subunits [11] or
Kir2.1 mutations [4,12] have been implicated in the development of
long QT syndrome, which is characterized by abnormalities of
repolarization that is predisposed to cardiac arrhythmias and an
increased risk of sudden death [4–6].
Protein tyrosine kinases (PTKs), including receptor PTKs (e.g. EGFR
kinase, epidermal growth factor receptor kinase) and nonreceptor PTKs
(e.g. Src-related kinases) are responsible for transducing key extracel-lular signals that mediate events such as cell growth, differentiation,
embryonic development, metabolism, and immune system function
[13,14]. PTKs regulate different types of ion channels [14], including L-
type Ca2+ current (ICa.L) [15], volume-sensitive Cl− current (ICl.vol) [16],
voltage-gated K+ channels, e.g. cardiac delayed rectiﬁer currents (IKs
and IhERG) [17–20], Kv2.1 current [21], Kv4.3 current [22] as well as the
voltage-gated Na+ current (INa) [23,24]. The phosphorylation of ion
channels at tyrosine residues has been shown to up-regulate voltage-
gated K+ currents [17–19,21,22,25] and INa [23,24]. However, the
controversial results were obtained regarding the PTK regulation of
Kir2.1 and/or native cardiac IK1. Wischmeyer and colleagues ﬁrst
reported that native and cloned Kir2.1 channels expressed in tsA-201
cells were suppressed by direct tyrosine kinase phosphorylation based
on the evidence that protein tyrosine phosphatase (PTP) inhibitor
perorthovanadate suppressed the current, and the effect can be
countered by the PTK inhibitor genistein [26]. Similar results were
observed inhumanbladderurothelial cells [27] and inhumanmyoblasts
[28], inwhichgenistein increasedKir2.1 current. However, in rat cardiac
ventricular myocytes we found that IK1 was suppressed by genistein
[25]. The inhibitory effect of Kir2.1 and Kir2.3 channels by genisteinwas
also observed by Zhao and colleagues in HEK 293 cells expressing Kir
channel genes [29]. Therefore, it is unclear whether Kir2.1 channels are
down-regulated or up-regulated by tyrosine phosphorylation. The
present study was designed to determine this regard in HEK 293 cells
stably expressing Kir2.1 gene using whole-cell patch clamp, immuno-
precipitation, Western blot, and mutagenesis approaches. We found
1994 D.-Y. Zhang et al. / Biochimica et Biophysica Acta 1808 (2011) 1993–1999that genistein and the EGFR kinase inhibitor AG556, but not the Src-
family inhibitor PP2, inhibited Kir2.1 channels via reducing tyrosine
phosphorylation of the channel protein.
2. Materials and methods
2.1. Cell culture, mutagenesis and gene transfection
The established HEK 293 cell line [30] stably expressing human
Kir2.1 cDNA (generously provided by Dr. Carol A. Vandenberg) was
cultured in Dulbecco's modiﬁed eagle's medium (DMEM, Invitrogen,
Hong Kong) supplemented with 10% fetal bovine serum and 400 μg/ml
G418 (Invitrogen). The Kir2.1 channel mutants, Y242A, Y242F, Y336A
and Y366A generated using the QuickChange Site-directedMutagenesis
kit (Stratagene), were transiently expressed inHEK 293 cells using 10 μl
of Lipofectamine 2000™ with 4 μg of Kir2.1 mutant cDNA in pcDNA3
vector. The point mutants were conﬁrmed with DNA sequencing. Cells
used for electrophysiology were seeded on a glass cover slip.
2.2. Solution and chemicals
Tyrode solution contained (mM) NaCl 140, KCl 5.4, MgCl2 1.0, CaCl2
1.0, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 10.0
and glucose 10 (pH adjusted to 7.3 with NaOH). For whole-cell
recordings, the pipette solution contained (mM) KCl 20, K-aspartate
110, MgCl2 1.0, HEPES 10, ethyleneglycoltetraacetic acid (EGTA) 5, GTP
0.1, Na2-phosphocreatine 5 and Mg-ATP 5 (pH adjusted to 7.2 with
KOH). 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]
pyrimidin-4-amine (PP2) was purchased from Tocris (Bristol, UK). All
other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Stock solutions of genistein (100 mM), daidzein (100 mM), tyrphostin
AG556 (100 mM), AG 1295 (20 mM), and PP2 (10 mM) were made
with dimethylsulfoxide (DMSO), divided into aliquots and stored at
−20 °C. Sodium orthovanadate (Sigma-Aldrich) stock solution
(200 mM) was made with distilled water, and pH value was adjusted
to 9.0.
2.3. Electrophysiology
Cells on a coverslip were transferred to a cell chamber (0.5 ml)
mountedon the stage of an invertedmicroscope (Diaphot,Nikon, Japan)
and superfused at ~2 ml/minwith Tyrode solution.Whole-cell currents
were recorded as described previously [30,31]. Brieﬂy, borosilicate glass
electrodes (1.2-mm OD) were pulled with a Brown–Flaming puller (P-
97, Sutter Instrument, Novato, CA) and had tip resistances of 2–3 MΩ
whenﬁlledwith thepipette solution. A 3 MKCl–agar bridgewasused as
the reference electrode. The tip potential was zeroed before the patch
pipette touched the cell. After a gigaohm-seal was obtained by negative
suction, the cell membrane was ruptured by applying gentle negative
pressure to establish thewhole cell conﬁguration. Series resistance (Rs)
was 3–5 MΩ and was compensated by 80% to minimize voltage errors.
The liquid junction potential (~12 mV) was not corrected in the
experiments. Membrane currents were measured using an EPC-10
ampliﬁer and Pulse software (Heka Elektronik, Lambrecht, Germany).
Commandpulsesweregeneratedbya12-bit digital-to-analog converter
controlled by Pulse software. Current signals were low-pass ﬁltered at
5 kHz, recorded and stored in the hard disk of an IBM compatible
computer. All experiments were conducted at room temperature (22–
23 °C).
2.4. Immunoprecipitation and Western blotting
The immunoprecipitation and Western blotting were performed
using the procedure described previously [17–19]. Cells were treated
respectively with 1 mM orthovanadate, 30 μM AG556, orthovanadate
plusAG556, 50 μMgenistein, 1 mMorthovanadate plus 50 μMgenisteinand 10 μM PP2 for 30 min at room temperature, and centrifuged
(1500 rpm for 10 min) at 4 °C. The cell pellet was then lysed with the
lysis buffer containing (mM) 25 Tris, 150 NaCl, 1.0 NaF, 1.0 EDTA, 1.0
VO4−3, 1.0 phenylmethylsulfonyl ﬂuoride, and 1%Na deoxycholate, 0.1%
SDS, 1% Triton X-100, 1 μg/ml leupeptin, and 1 μg/ml aprotinin. Protein
quantiﬁcation of the lysateswasmade using a protein assay reader (Bio-
Rad Laboratories, Hercules, CA, USA), and diluted to equal concentra-
tions. Proteinswere immunoprecipitated overnight at 4 °C using 2 μg of
anti-Kir2.1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and 100 μl of protein A beads (Millipore, Billerica, MA, USA). Immuno-
precipitated proteins bound to pelleted protein A beads were washed
thoroughly in PBS, denatured in Laemmli sample buffer, separated using
SDS-PAGE, and electroblotted onto nitrocellulose membranes. The
immunoblots were probed with anti-phosphotyrosine antibody
(1:1000, Cell signaling Technology Inc., Danvers, MA, USA) overnight
at 4 °C in a blocking solution containing 5% BSA in TBS and 0.1% Tween
20, and subsequently treated with goat anti-mouse IgG-HRP antibody
(1:5000, Santa Cruz Biotechnology) for 1 h at room temperature. Blots
were developed with enhanced chemiluminescence (ECL, Amersham
Biosciences, Sweden) and exposed on a X-ray ﬁlm. The blots were then
stripped and reprobed with the anti-Kir2.1 channel antibody to
determine total Kir2.1 channel proteins. The ﬁlm was scanned, imaged
by a Bio-Imaging System (Syngene, Cambridge, UK), and analyzed via
GeneTools software (Syngene).
2.5. Statistical analysis
Nonlinear curve-ﬁtting was performed using Pulseﬁt (HEKA) and
Sigmaplot (SPSS, Chicago, IL). Paired and/or unpaired Student's t-test
were used as appropriate to evaluate the statistical signiﬁcance of
differences between two group means, and ANOVA was used for
multiple groups. Group data are expressed as means±SEM. P values
less than 0.05 were considered to indicate statistically signiﬁcant
difference.
3. Results
3.1. Inhibition of Kir2.1 current by genistein
Fig. 1A shows the time course of Kir2.1 current (at −120 mV)
recorded in a representative cell with a ramp protocol from −120 to
0 mV from a holding potential of−40 mVevery 20 s in the absence and
presence of 30 μM genistein. Current–voltage (I–V) relation curves of
Kir2.1 current are shown in right of the panel. Genistein inhibited Kir2.1
current, and the inhibitory effect recovered upon washout (n=7).
Similarly, voltage-dependent Kir2.1 current elicited by the voltage step
protocol as shown in the inset was reversibly suppressed by 30 μM
genistein (Fig. 1B). This result is comparable to the previous reports in
native cardiac IK1 [25] and Kir2.1 channels expressed in HEK 293 cells
[29]. However, the result is different from those in tsA-201 cells
expressing Kir2.1 gene [26], human bladder urothelial cells [27] and
human myoblasts [28], in which genistein increases the Kir current.
To exclude possible direct channel-blocking effect by genistein, we
tested whether daidzein (a PTK-inactive analog of genistein) could
suppress Kir2.1 current. Fig. 1B shows that voltage-dependent Kir2.1
current was slightly decreased by 30 μM daidzein, and the effect
recovered on washout. Fig. 1D illustrates the mean percent values of
Kir2.1 current at −120 mV in the absence and presence of equimolar
genistein (n=7) and daidzein (n=5). Genistein at 10, 30, and 100 μM
inhibited Kir2.1 current by 8.6±3.3%, 16.3±4.1%, and 43.9±6.9%,
respectively (Pb0.05 or Pb0.01 vs. control). However, daidzein had no
effect on the current at 10 μM, and a slight inhibitionwas seen at 30 and
100 μM (6.3±1.3% and 9.3±1.2%, Pb0.05 vs. control). The effect of
daidzein on Kir2.1 current wasweaker than that of equimolar genistein
(Pb0.05 or Pb0.01) which suggests that the inhibitory effect of
genistein on Kir2.1 current is likely mediated by PTK pathway.
Fig. 1. Inhibition of Kir2.1 current by genistein and daidzein. A. Time course of Kir2.1
current (at−120 mV) recorded in a representative cells activated by a 2-s voltage ramp
from−120 to 0 mV. I–V relationships of Kir2.1 current at corresponding time points are
shown in right of the panel. B. Voltage-dependent Kir2.1 current recorded in a typical
experiment with the voltage protocol as shown in the inset in the absence and presence
of 30 μM genistein. Arrow indicates zero current level. C. Voltage-dependent Kir2.1
current recorded in a typical experiment with the voltage protocol as shown in the inset
of B in the absence and presence of 30 μM daidzein. D. Mean percent values of Kir2.1
current measured at end of step protocol (−120 mV) from zero level in the absence
and presence of 10, 30, and 100 μM genistein or daidzein (n=5–7, *Pb0.05, **Pb0.01
vs. control; #Pb0.05, ##Pb0.01 vs. daidzein).
Fig. 2. Genistein and orthovanadate effects on Kir2.1 current. A. Voltage-dependent
Kir2.1 current recorded in a representative cell with the voltage protocol as shown in
the inset during control, in the presence of 50 μM genistein, and genistein plus 1 mM
orthovanadate (OV). B. Time-course of Kir2.1 current recorded in a typical experiment
with a 2-s ramp voltage protocol from −120 to 0 mV from a holding potential of
−40 mV, in the absence and presence of 50 μM genistein, and genistein plus 1 mM
orthovanadate. The current was measured at−120 mV from zero. I–V relationships of
Kir2.1 current at corresponding time points are shown in right of the panel. C. Mean
percent values of Kir2.1 current measured at end of voltage step (−120 mV) in the
absence and presence of 50 μM genistein or genistein plus 1 mM orthovanadate. (n=6,
**Pb0.01 vs. control, #Pb0.05 vs. genistein alone).
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the effect should be countered by the PTP inhibitor orthovanadate.
Orthovanadate at 1 mMhadnoeffect onKir2.1 current (n=11, data not
illustratively shown); however, it antagonized the inhibitory effect of
Kir2.1 current by genistein. Fig. 2A shows the voltage-dependent Kir2.1
current recorded in a typical experiment. Genistein at 50 μM decreased
the current, and the inhibitory effectwas countered by co-application of
1 mM orthovanadate. Similar results were seen in the time course of
Kir2.1 current recorded in a representative cell with a ramp protocol
from −120 to 0 mV from a holding potential of −40 mV (Fig. 2B).
Fig. 2C summarizes the mean percent values of Kir2.1 current in the
absence and presence of genistein or genistein plus orthovanadate.
Genistein at 50 μM suppressed Kir2.1 current (at−120 mV) to 75.5±
1.9% of control (360.9±40.0 pA/pF for control to 265.9±34.4 pA/pF
for genistein, n=6, Pb0.01), and the inhibitory effect was reversed to
92.2±4.25% (336.9±39.1 pA/pF) by co-application of genistein and
1 mM orthovanadate (n=6, Pb0.01 vs. genistein). These results
support the notion that the inhibition of Kir2.1 current by genistein is
mediated by PTKs.
To investigate which speciﬁc PTK mediates Kir2.1 channel
regulation, AG556 (a highly selective EGFR kinase inhibitor) [32,33],AG1295 (a selective PDGFR kinase inhibitor) [34], and PP2 (a selective
Src-family kinase inhibitor) [35] were employed in the following
experiments.
3.2. Inhibition of Kir2.1 current by AG556
Fig. 3A shows the voltage-dependent Kir2.1 current recorded in a
representative cell in the absence and presence of 30 μM AG556 or
AG556 plus 1 mM orthovanadate. AG556, like genistein, remarkably
inhibited Kir2.1 current, and the inhibition was almost fully countered
by co-application of orthovanadate. Fig. 3B displays the time course of
Kir2.1 current recorded in typical of experiment with a 200-ms voltage
step from −40 to −120 mV every 20 s. The inhibitory effect of step
Kir2.1 current by 30 μM AG556 was antagonized by 1 mM orthovana-
date. I–V relationships of Kir2.1 current in the absence or presence of
30 μM AG556 or AG556 plus 1 mM orthovanadate are illustrated in
Fig 3C. AG556 signiﬁcantly decreased Kir2.1 current at −120 to
−90 mV and −50 to −30 mV (n=6, Pb0.05 or Pb0.01 vs. control),
and the inhibition was countered by co-application of orthovanadate
(Pb0.05 or Pb0.01 vs. AG556 alone). Fig. 3D summarizes the mean
percent values of Kir2.1 current (at−120 mV) with 30 μM AG556 and
AG556 plus 1 mM orthovanadate. AG556 (30 μM) inhibited Kir2.1 to
81.3±2.3% of control (348.0±39.0 pA/pF of control to 281.5±38.2 pA/
pF of AG556, n=6, Pb0.01), and the inhibition was reversed to 99.44
±0.6% (346.6±40.5 pA/pF, Pb0.01 vs. AG556 alone) of control by
orthovanadate. These results suggest that reduction of Kir2.1 current by
Fig. 3. Effects of AG556 on Kir2.1 current. A. Voltage-dependent Kir2.1 current recorded in a representative cell with a voltage protocol as shown in the inset of Fig. 1B during control,
after application of 30 μMAG556, and AG556 plus 1 mM orthovanadate (OV). B. Time-course of Kir2.1 current recorded in a typical experiment with a 200-ms voltage step from−40
to−120 mV from a holding potential of−40 mV, in the absence and presence of 30 μMAG556, and AG556 plus 1 mM orthovanadate. Original current traces at corresponding time
points are shown in right of the panel. C. I–V relationships of Kir2.1 current measured at end of the voltage steps as shown in A (n=6, one way ANOVA, *Pb0.05, **Pb0.01 vs.
control). D. Mean percent values of Kir2.1 current determined at end of voltage step (−120 mV) in the absence and presence of 30 μMAG556, and AG556 plus 1 mM orthovanadate
(n=6, **Pb0.01 vs. control; #Pb0.05 vs. AG556 alone).
Fig. 4. Effect of AG1295 and PP2 on Kir2.1 current. A. Voltage-dependent Kir2.1 current
recorded in a representative cell with the protocol shown in the inset in the absence
and presence of 10 μM AG1295. B. Voltage-dependent Kir2.1 current recorded in a
typical experiment in the absence and presence of 10 μMPP2. C. Mean percent values of
Kir2.1 current determined at end of voltage step (−120 mV) in the absence and
presence of 10 μM AG1295, or 10 μM PP2 (n=5 each group).
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had no effect onbasal Kir2.1 current (n=6, data not shown), suggesting
that tyrosine phosphorylation level of the channel is at a saturated state.
3.3. Effect of PP2 and AG1295 on Kir2.1 current
Fig. 4 shows that the selective PDGFR kinase inhibitor tyrphostin
AG1295 (10 μM, 20 times higher than IC50 for inhibiting PDGFR
tyrosine kinase) [36], and the membrane permeable Src-family kinase
inhibitor PP2 (10 μM, 2000 times higher than IC50 for inhibiting Src-
kinases) [34,35,37] had no inhibitory effect on Kir2.1 current. In the
cells treated with AG1295, the mean values of Kir2.1 current at
−120 mV were −354.7±36.8 and −347.9±43.3 pA/pF before and
after AG1295 treatment for 8 min (n=5, P=NS). In the cells treated
with PP2, the mean values of Kir2.1 current were −389.2±48.5 and
−380.7±44.8 pA/pF before and after PP2 treatment (n=5, P=NS).
3.4. Tyrosine phosphorylation level of Kir2.1 channels
Fig. 5A displays the conﬁrmative data showing signiﬁcant
expression of EGFR protein in HEK 293 cells with/without Kir2.1
gene expression, which is consistent with previous report [38].
Tyrosine phosphorylation of Kir2.1 channels was examined using
immunoprecipitation and Western blot analysis. Fig. 5B illustrates
tyrosine phosphorylation level of Kir2.1 channels in the absence and
presence of 1 mM orthovanadate, 50 μM genistein, 1 mM orthovana-
date plus genistein, 10 μM PP2, 100 ng/ml EGF, 30 μM AG556, 1 mM
orthovanadate plus AG556. Orthovanadate and EGF had no effect on
tyrosine phosphorylation level of Kir2.1 channels, suggesting that
basal tyrosine phosphorylation level of Kir2.1 channel is at a saturated
state. Genistein and AG556, but not PP2, signiﬁcantly reduced the
phosphorylation level. The reduction was antagonized by pretreat-
ment (20 min) with 1 mM orthovanadate. Fig. 5C summarizes the
mean percent values of quantitative tyrosine phosphorylation levels
of Kir2.1 channels. The tyrosine phosphorylation level of Kir2.1
channels was reduced to 74.1%±4.9% of control (n=5 experiments)
in cells treated with 50 μM genistein (Pb0.01 vs. control), and the
inhibition was partially reversed to 84.0±4.0% of control in the cells
treated with 1 mM orthovanadate plus genistein (P=NS vs. genisteinalone). In cells treated with 30 μM AG556, the phosphorylation level
was 78.7±3.5% of control (Pb0.01 vs. control), and 92.4±1.6% in the
cells treatedwith 1 mMorthovanadate plus AG556 (Pb0.05 vs. AG556
alone). These results indicate that the inhibition of EGFR kinase
reduces tyrosine phosphorylation of Kir2.1 channel protein.
Fig. 5. EGFR expression in HEK 293 cells and tyrosine phosphorylation levels of Kir2.1
channels. A. Western blotting image of anti-EGFR antibody in HEK293 cells with/
without Kir2.1 gene transfection. B. Upper panel, protein lysates were immunopreci-
pitated with anti-Kir2.1 channel antibody, Western blots were then prepared and
probed with anti-phosphotyrosine(Tyr(P)) antibody. Lower panel, Western blots of cell
lysates, probed with anti-Kir2.1 channel antibody. C. Histogram summarizes the mean
values of the relative levels of tyrosine-phosphorylated Kir2.1 channel protein analyzed
by the densitometry. The amount of protein from the immunoprecipitation as in B was
normalized to those from theWestern blots of Kir2.1 channels. Relative phosphorylated
protein level (n=5 experiments) is expressed as a percentage of the vehicle control.
**Pb0.01, *Pb0.05 (ANOVA) vs. vehicle control, #Pb0.05 vs. AG556 alone. OV,
orthovanadate; EGF, epidermal growth factor.
Fig. 6. Single point mutations of Kir2.1 channels and AG556 effects. A. WT and mutant Kir2
potential of −40 mV in the absence and presence of 30 μM AG556. B. Mean percent vol
(−120 mV) from the zero (broken line) in the absence or presence of 3, 10, and 30 μM A
**Pb0.01 vs. control or Y242A or Y242F (n=5–12 experiments).
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The predicted potential PTK phosphorylation sites were examined
with the software NetPhos 2.0 (www.cbs.dtu.dk/cgi-bin). The mutants
of the top three potential PTK phosphorylation sites Y242, Y336 and
Y366 were generated by substituting tyrosine with alanine or
phenylalanine. Fig. 6A shows the inhibitory response ofWT andmutant
Kir2.1 currents (recordedwith a 200-ms voltage step to−120 mV from
−40 mV) to the EGFR kinase AG556 (30 μM). A slight reduction of
Kir2.1 current was observed in Y242A or Y242F with 30 μM AG556,
whereas a signiﬁcantdecrease of the currentwas seen inWT, Y336Aand
Y366A Kir2.1 currents. Fig. 6B illustrates themean percent values ofWT
and different mutant Kir2.1 channels with 3, 10, and 30 μM AG556
relative to control (before AG556 treatment). AG556 at 10 and 30 μM
signiﬁcantly inhibited Kir2.1 current (at −120 mV, n=6–7 experi-
ments, Pb0.05 or Pb0.01 vs. control) in WT (by 12.7±1.9 and 22.2±
2.1%), Y336A (13.5±2.1 and 20.8±2.2%) and Y366A (14.6±2.5 and
21.4±2.9%), but not in mutants Y242A (4.7±2.3 and 5.4±3.3%) and
Y242F (3.0±4.8 and 6.6±3.7%).
The results of further immunoprecipitation and Western blot
analysis showed that tyrosine phosphorylation level was dramatically
reduced in cells expressing in Y242F Kir2.1 mutants (Fig. 7A). These
results suggest that the tyrosine phosphorylation site of Kir2.1
channels is located at the Y242 residue (Fig. 7B), which is comparable
to that of the previous report [26,28].
4. Discussion
The present study demonstrates that the PTK inhibitor genistein or
AG556, but not AG1295 and PP2, decreases activity of Kir2.1 channels
stably expressed in HEK 293 cells. The inhibitory effect is countered by
the PTP inhibitor orthovanadate. Protein tyrosine phosphorylation level
of Kir2.1 channels is reduced by the broad spectrum PTK inhibitor
genistein or EGFR kinase inhibitor AG556, and the reduced phosphor-
ylation level is reversed by orthovanadate. In addition, site-directed
mutation reveals that EGFR kinase is located at Y242 of Kir2.1 channels..1 channel currents recorded with a 200-ms voltage step to −120 mV from a holding
umes of WT and mutant Kir2.1 channel currents determined at end of voltage step
G556. Y242A and Y242F mutants were not sensitive to inhibition by AG556. *Pb0.05,
Fig. 7. Reduced tyrosine phosphorylation of Y242mutant. A. Images andmean values of
tyrosine phosphorylation for WT and Y242F Kir2.1 channels with and without AG556
treatment (n=3 experiments, **Pb0.01 vs. WT, #Pb0.01 vs. WT and WT plus AG556).
B. Schematic model for regulation of Kir2.1 channels by EGFR kinases. Tyrosine 242
residue of Kir2.1 channels is phosphorylated by EGFR kinase. Phosphorylation of
tyrosine by one or more steps (dashed line) favors Kir2.1 channel activation, whereas
inhibition of phosphorylation may favor channel closure. Genistein or AG556 inhibits
EGFR tyrosine kinase and reduces the phosphorylation; the inhibition is countered by
the PTP inhibitor orthovanadate (OV).
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the negatively charged head groups of PIP2 with charged residues in the
C-terminal region of the Kir channel [8–10], cardiac IK1 and/or Kir2.1
channels are down-regulated by the β-adrenoceptor against isoproter-
enol or adenylate cyclase activator forskolin via activating cAMP/protein
kinase A [1,39], and by α1-adrenoceptor agonist methoxamine via
activating protein kinase C [40]. Acidosis also modulates IK1 in a species-
dependent manner [1]. We and others have demonstrated that cardiac
IK1 and/or Kir2.1 channels are regulated by PTKs [25–28], although the
response of native or cloned Kir2.1 channels to PTK inhibitors and/or
tyrosinephosphorylation is different (down-regulationorup-regulation)
in various expression systems and/or cell types.
The present study has demonstrated that endogenous EGFRs are
present in HEK 293 cells (Fig. 5A), consistent with the previous
observation [38]. Inhibition of tyrosine phosphorylation of Kir2.1
channels down-regulates the current. First, Kir2.1 channels stably
expressed in HEK 239 cells were reversibly suppressed by the broad
spectrum PTK inhibitor genistein, consistent with the previous
observation in rat cardiac ventricular myocytes [25] and in HEK 293
cells expressing Kir2.1 channels [29]. Second, genistein exhibits a
stronger inhibition of Kir2.1 current than that of the PTK-inactive analog
daidzein (Fig. 1). Third, the PTP inhibitor orthovanadate almost fully
countered the suppression of cardiac IK1 [25] or Kir2.1 current by
genistein (Fig. 2) or by the selective EGFR kinase inhibitor AG556
(Fig. 3). Fourth, genistein and AG556 decreased tyrosine phosphoryla-
tion level of Kir2.1 channels and the reduced phosphorylation level wassigniﬁcantly antagonizedbyorthovanadate (Fig. 5).Moreover,we found
that Y242 is the PTK phosphorylation site since the site-directed
mutation of Y242 lost the response to the EGFR kinase inhibitor AG556
(Fig. 6). However, the PDGFR kinase inhibitor AG1295 (10 μM, 20 times
higher than IC50 for inhibiting PDGFR tyrosine kinase) [34] and the Src-
family inhibitor PP2 (10 μM, 2000 times higher than IC50 for inhibiting
Src-family kinase) [35] had no effect on Kir2.1 channels (Fig. 4). These
results support thenotion that activity of human cardiac Kir2.1 channels
is up-regulatedbyphosphorylatingY242 residue in the channel by EGFR
kinase. Orthovanadate and EGF had no effect on Kir2.1 current or
phosphorylation, this is likely related to the saturated phosphorylation
of the channels as observed in cardiac IKs [19] and hERG channels [17].
This differs from native guinea pig cardiac INa [23] and Kir2.3 channels
expressed in HEK 293 cells [41], in which ion channel proteins can be
signiﬁcantly upregulated by orthovanadate or EGF application.
However, in tsA-201 cells expressing rat Kir2.1 channels, Wisch-
meyer and colleagues found that the PTP inhibitor perorthovanadate
decreased the current, and the inhibitory effect was countered by the
PTK inhibitor genistein. A similar effect was observed in native Kir2.1
channels in rat basophilic leukocytes. Perorthovanadate failed to
suppress the mutant Y242F channels expressed in tsA-201 cells and
Xenopus oocytes. Moreover, Kir2.1 current was rapidly suppressed by
nerve growth factors (NGF) or EGF, or insulin in Xenopus oocytes co-
expressing Kir2.1 channels and growth factor receptors. These results
suggest that an increased phosphorylation of Kir2.1 at Y242 by
inhibiting PTPs or activating PTKs down-regulates Kir2.1 current in
neuronal cells [26]. The tyrosine phosphorylation site Y242 is identical
to that observed in the present study (Fig. 5), although the consequence
of the channel phosphorylation is opposite. It is unknown whether this
opposite regulatory effect of Kir2.1 channels by PTKs is due to different
expression systems, cell types and/or experimental conditions.
Both EGFR kinase and Src-related kinases modulate the α-subunit
hERG current of human cardiac IKr [17]. Interestingly, antagonistic
regulation of swelling-activated Cl− current (ICl,swell) by Src and EGFR
protein tyrosine kinases was observed in rabbit ventricular myocytes
[42,43]. PP2 stimulated, but the EGFR kinase inhibitor PD-153035
inhibited ICl,swell [43]. However, Src-family tyrosine kinase regulation
is not the case for recombinant cardiac IKs, Kir2.3 channel, and Kir2.1
channel, because PP2 had no effect on the IKs [19], Kir2.3 [41], and
Kir2.1 current (Fig. 4) and also no effect on tyrosine phosphorylation
of these channels. This suggests variable regulation responses of ion
channels to tyrosine kinases.
The altered property of Kir2.1 currents was observed in mutations
(Fig. 6), i.e. a fast onset of the currents with voltage changes and a fast
inactivation component was clearly visible in currents of Kir2.1
mutants with alanine. The possible alteration of these mutations may
be related to channel general functionality rather than a speciﬁc
action on tyrosine phosphorylation. The similar phenomenonwas also
observed in Kir2.3 channels [41].
The Kir2.1 channel is not only responsible for repolarization of the
action potential, but also for stabilization of the resting membrane
potential in cardiac myocytes [1]. The present and previous studies
support the notion that PTK inhibitors inhibit Kir2.1 channels and
cardiac IK1 [25] by EGFR kinase, which suggests that the tyrosine
phosphorylation of Kir2.1 promotes the channel opening in cardiac
myocytes. The dysfunction of Kir2.1 channels can cause long QT
syndrome and increase the risk of sudden death [4–6]. Therefore,
regulation of cardiac Kir2.1 channels by EGFR kinase may affect cardiac
repolarization and excitability.
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